Xiang Xiaochen, He Mingxin, Li Xinquan, Wang Jun, Xu Xiaojun, Meng Jingye, Feng Jialu, Guo Zhi, Wang Qiang
Institute of Infection, Immunology, and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan Wuchang Hospital, Medical College, Wuhan University of Science and Technology, Wuhan, China.
Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Guangdong, China.
Transplant Proc. 2025 May;57(4):627-637. doi: 10.1016/j.transproceed.2025.02.042. Epub 2025 Mar 26.
Immune system impairment and chemotherapies prior to autologous hematopoietic stem cell transplantation (auto-HSCT) significantly increase the risk of respiratory tract infections (RTIs), especially within 100 days after HSCT. Prophylaxis of RTIs among patients with HSCT are of high importance, clinical experiences have been learnt previously that oropharyngeal probiotic is safe and able to significantly reduce RTIs among patients with recurrent RTIs in both children and adults, the aim of this study is to explore the safety and preventive effects of oropharyngeal probiotics BP-OM1 on RTIs among patients after HSCT.
Sixteen subjects aged between 18 and 65 years old who underwent HSCT were enrolled in a multicenter, randomized controlled trial. The subjects were randomly assigned to the oropharyngeal probiotics group and the control group. Patients were intervened and monitored for 130 days.
Less duration and severity of presented RTI-like symptoms observed among patients in the probiotic group resulted in a significantly decreased days of antibiotic consumption post-HSCT. No oropharyngeal probiotic-related adverse events were reported throughout this study, indicating that oropharyngeal probiotic BP-OM1 administration is safe for patients whose hematopoietic system are well reconstructed post-HSCT.
The administration of oropharyngeal probiotic BP-OM1 could potentially be a safe self-care approach for patients who underwent HSCT to manage the RTI prevention and reduce the risks of developing lower respiratory tract infection (LRTI), which favors the rational use of antibiotics, which is associated with a reduced risks colonization of multi-drug resistance microorganisms.
自体造血干细胞移植（auto-HSCT）前的免疫系统损害和化疗会显著增加呼吸道感染（RTIs）的风险，尤其是在HSCT后的100天内。预防HSCT患者的RTIs非常重要，此前已有临床经验表明，口服益生菌对儿童和成人复发性RTIs患者是安全的，并且能够显著降低RTIs的发生率。本研究的目的是探讨口服益生菌BP-OM1对HSCT后患者RTIs的安全性和预防效果。
16名年龄在18至65岁之间接受HSCT的受试者参加了一项多中心随机对照试验。受试者被随机分配到口服益生菌组和对照组。对患者进行130天的干预和监测。
益生菌组患者出现的类似RTI症状的持续时间和严重程度较轻，导致HSCT后抗生素使用天数显著减少。在整个研究过程中，未报告与口服益生菌相关的不良事件，这表明对于HSCT后造血系统已良好重建的患者，口服益生菌BP-OM1是安全的。
对于接受HSCT的患者，口服益生菌BP-OM1可能是一种安全的自我护理方法，可用于预防RTI并降低发生下呼吸道感染（LRTI）的风险，这有利于合理使用抗生素，与降低多重耐药微生物定植风险相关。
